Hosein Shahsavarani

Dr. Hosein Shahsavarani

Shahid Beheshti University, Tehran, Tehrān, Iran
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2019 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
SMSharif Moradi
Sharif Moradi
HMHamid Mahdizadeh
Hamid Mahdizadeh
TŠTomo Šarić
Tomo Šarić
JKJohnny Kim
Johnny Kim
JHJavad Harati
Javad Harati
JMJoseph B. Moore
Joseph B. Moore
Induced pluripotent stem cells (iPSCs) can self-renew indefinitely in culture and differentiate into all specialized cell types including gametes. iPSCs do not exist naturally and are instead generated (“induced” or “reprogrammed”) in culture from somatic cells through ectopic co-expression of defined pluripotency factors. Since they can be generated from any healthy person or patient, iPSCs are considered as a valuable resource for regenerative medicine to replace diseased or damaged tissues. In addition, reprogramming technology has provided a powerful tool to study mechanisms of cell fate decisions and to model human diseases, thereby substantially potentiating the possibility to (i) discover new drugs in screening formats and (ii) treat life-threatening diseases through cell therapy-based strategies. However, various legal and ethical barriers arise when aiming to exploit the full potential of iPSCs to minimize abuse or unauthorized utilization. In this review, we discuss bioethical, legal, and societal concerns associated with research and therapy using iPSCs. Furthermore, we present key questions and suggestions for stem cell scientists, legal authorities, and social activists investigating and working in this field.

1 November 2012 in Biotechnology Advances
Verified
Journal Article
Closed access
Hosein ShahsavaraniHosein Shahsavarani
Hosein Shahsavarani
MSMinetaka Sugiyama
Minetaka Sugiyama
YKYoshinobu Kaneko
Yoshinobu Kaneko
BCBoonchird Chuenchit
Boonchird Chuenchit
SHSatoshi Harashima
Satoshi Harashima

22 March 2023 in Molecular Therapy
Verified
Journal Article
Open access
ZNZohreh Najminejad
Zohreh Najminejad
FDFatemeh Dehghani
Fatemeh Dehghani
YMYousef Mirzaei
Yousef Mirzaei
AMAli Hussein Mer
Ali Hussein Mer
SSSeyyed Amirreza Saghi
Seyyed Amirreza Saghi
MAMeghdad Abdollahpour-Alitappeh
Meghdad Abdollahpour-Alitappeh
Antibody-drug conjugates (ADCs) are a promising class of cancer biopharmaceuticals that exploit the specificity of a monoclonal antibody (mAb) to selectively deliver highly cytotoxic small molecules to targeted cancer cells, leading to an enhanced therapeutic index through increased antitumor activity and decreased off-target toxicity. ADCs hold great promise for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after the approval and tremendous success of trastuzumab emtansine and trastuzumab deruxtecan, representing a turning point in both HER2-positive breast cancer treatment and ADC technology. Additionally and importantly, a total of 29 ADC candidates are now being investigated in different stages of clinical development for the treatment of HER2-positive breast cancer. The purpose of this review is to provide an insight into the ADC field in cancer treatment and present a comprehensive overview of ADCs approved or under clinical investigation for the treatment of HER2-positive breast cancer.

5 March 2018 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
SYShin-Ya Yasuda
Shin-Ya Yasuda
TITatsuhiko Ikeda
Tatsuhiko Ikeda
Hosein ShahsavaraniHosein Shahsavarani
Hosein Shahsavarani
NYNoriko Yoshida
Noriko Yoshida
BNBhavana Nayer
Bhavana Nayer
KHKouichi Hasegawa
Kouichi Hasegawa

1 January 2021 in Carbohydrate Polymers
Verified
Journal Article
Closed access
FNFatemeh Noormohammadi
Fatemeh Noormohammadi
MNMohammad Nourany
Mohammad Nourany
GSGity Mir Mohamad Sadeghi
Gity Mir Mohamad Sadeghi
PWPeng-Yuan Wang
Peng-Yuan Wang
Hosein ShahsavaraniHosein Shahsavarani
Hosein Shahsavarani

1 October 2020 in Gene
Verified
Journal Article
Closed access
ASAli Salehi
Ali Salehi
MMMohammad Amin Mobarhan
Mohammad Amin Mobarhan
JMJavad Mohammadi
Javad Mohammadi
Hosein ShahsavaraniHosein Shahsavarani
Hosein Shahsavarani
MSMohammad Ali Shokrgozar
Mohammad Ali Shokrgozar
AAAtefeh Alipour
Atefeh Alipour